Showing posts with label trigger point injections. Show all posts
Showing posts with label trigger point injections. Show all posts

Sunday, January 29, 2017

Lake Forest TMJ, Headaches, Migraines and Neuromuscular Approach To Definitive Personalized Treatment

The relationship of TMJ Disorders to Headaches and Migraines are well documented in both medical and dental literature.  The primary connection is via the Trigeminal Nerve.  The Trigeminal Nerve is often called the "Dentists Nerve" but the Trigeminal nerve is also at the center of each and every headache and migraine treated by physicians and neurologists.  The science behind this connection is two-fold.  The Trigeminal nerve also controls the blood flow to the anterior two thirds of the meninges of the brain.

Sinus headaches are usually treated by ENT's or Otolaryngologists but the Trigeminal Nerve is also front and center in both acute and chronic sinus pain.  Multiple studies have shown that most diagnosis of sinus infections causing pain are in fact incorrect.  

There are many documented cases of complete relief of all of these disorders with eliminated with Neuromuscular Dental Orthotics especially when combined with treatment of Myofascial Pain Disorders (MPD).  There are over 100 Chicago patient Testimonials at: 
https://www.youtube.com/channel/UCk9Bfz6pklC7_UluWFHzLrg

WWW.ThinkBetterLife.com is the website of my new office dedicated to treatment of both TMJ Disorders, Sleep Disorders including Snoring & Sleep Apnea and chronic headaches and migraines.

The National Heart Lung and Blood Institute (NHLBI) of the National Institute of Health (NIH) has published a report "CARDIOVASCULAR AND SLEEP-RELATED CONSEQUENCES OF TEMPOROMANDIBULAR DISORDERS" that should be read by every patient with TMJ disorders, Morning Headaches, Chronic Daily Headaches, Sleep Apnea, Snoring and migraines.
 https://www.nhlbi.nih.gov/files/docs/workshops/tmj_wksp.pdf

Sphenopalatine Ganglion Blocks are an amazing adjunct for treating chronic pain disorders.  It works via the autonomic nervous system and turns off the "Fight or Flight" reflex that is implicated in tension headaches, chronic anxiety and panic attacks.  www.sphenopalatineganglionblocks.com


Sunday, February 15, 2015

Treating and Preventing Migraines: Episodic vs Chronic New Article in Headache March 2015 Describes Barries to Optimal Treatment and Prevention

There is a new article " 2015 Mar;55 Suppl 2:103-22. doi: 10.1111/head.12505_2.

Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention." in Headache that describes the problems in finding optimal treatment.


In my experience the diagnosis of episodic or chronic migraine can actually harm the patient.  As headaches are classified it then limits the treatments that physicians offer.  I frequently find that wrong assumptions as to the cause of headaches is often the largest deterrent to successful treatment.  
The following video is a patient with severe headache that was relieved in just a few minutes time with Ttrigger Point Injections and muscle stretch.  The orgin was Myofascial Pain but the symptom was headache or migraine. When I saw this patient the first time she had been in constant excruciating pain for every minute of every day for 22 years.

Watch the video and then go www.thinkbetterlife.com testimonial page to see her first video. 

https://www.youtube.com/watch?v=-VA-amBnd8A

According to the article there are only five strategies for preventing episodic migraine and one  for preventing chronic migraine.  This fact is based on the idea that drug therapy is the method of preventing migraines.   " Five US Food and Drug Association strategies are approved for preventing episodic migraine, but only injections with onabotulinumtoxinA are approved for preventing chronic migraine. Identifying persons who require migraine prophylaxis and selecting and initiating the most appropriate treatment strategy may prevent progression from episodic to chronic migraine and alleviate the pain and suffering associated with frequent migraine. "


5.
 2015 Mar;55 Suppl 2:103-22. doi: 10.1111/head.12505_2.

Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention.

Abstract

Migraine is a common disabling primary headache disorder that affects an estimated 36 million Americans. Migraine headaches often occur over many years or over an individual's lifetime. By definition, episodic migraine is characterized by headaches that occur on fewer than 15 days per month. According to the recent International Classification of Headache Disorders (third revision) beta diagnostic criteria, chronic migraine is defined as "headaches on at least 15 days per month for at least 3 months, with the features of migraine on at least 8 days per month." However, diagnostic criteria distinguishing episodic from chronic migraine continue to evolve. Persons with episodic migraine can remit, not change, or progress to high-frequency episodic or chronic migraine over time. Chronic migraine is associated with a substantially greater personal and societal burden, more frequent comorbidities, and possibly with persistent and progressive brain abnormalities. Many patients are poorly responsive to, or noncompliant with, conventional preventive therapies. The primary goals of migraine treatment include relieving pain, restoring function, and reducing headache frequency; an additional goal may be preventing progression to chronic migraine. Although all migraineurs require abortive treatment, and all patients with chronic migraine require preventive treatment, there are no definitive guidelines delineating which persons with episodic migraine would benefit from preventive therapy. Five US Food and Drug Association strategies are approved for preventing episodic migraine, but only injections with onabotulinumtoxinA are approved for preventing chronic migraine. Identifying persons who require migraine prophylaxis and selecting and initiating the most appropriate treatment strategy may prevent progression from episodic to chronic migraine and alleviate the pain and suffering associated with frequent migraine. 
© 2015 American Headache Society.

KEYWORDS: 

chronic migraine; diagnosis; episodic migraine; iontophoretic transdermal system; onabotulinumtoxinA injection; treatment
PMID:
 
25662743
 
[PubMed - in process]

Saturday, July 16, 2011

Are Trigger Point Injections More Effective Than Botox In Treating TMD (TMJ) Myofascial Pain

A recent study in Pain. 2011 Apr 21 looked at botulinum toxin type A for treatment of persistent myofascial TMD pain. Saline was used as the placebo-control in this double blind study. The crossover study examined 21 patients Myofascial TMD with inadequate pain control.

The study was done to evaluate the effectiveness of botulinum toxin type A for treatment of persistent myofascial TMD pain but actually showed that Saline is normally considered an excellent placebo because there are no direct biological changes associated with saline. There was statistically no advantage to botulinum toxin type A over saline.

I hypothesize that the improvement in pain showed in the study with saline was a direct result of the injection, not what was injected. Dry needling has also been shown to be very effective treatment for myofascial trigger points associated with TMD. I utilize both dry needling and lidocaine injections for treating MPD. Treatment of myofascial trigger points is an extremely effective treatment for TMD pain.

Trigger Point Injections and Dry Needling remain on of the most effective treatments for myofascial TMD.


Pain. 2011 Apr 21. [Epub ahead of print]
Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study.
Ernberg M, Hedenberg-Magnusson B, List T, Svensson P.
Source

Unit of Clinical Oral Physiology, Department of Dental Medicine, Karolinska Institutet, Box 4064, SE 141 04 Huddinge, Sweden.
Abstract

Evidence of an effect by botulinum toxins is still lacking for most pain conditions. In the present randomized, placebo-controlled, crossover multicenter study, the efficacy of botulinum toxin type A (BTX-A) was investigated in patients with persistent myofascial temporomandibular disorders (TMD). Twenty-one patients with myofascial TMD without adequate pain relief after conventional treatment participated. A total of 50 U of BTX-A or isotonic saline (control) was randomly injected into 3 standardized sites of the painful masseter muscles. Follow-up was performed after 1 and 3months, followed by a 1-month washout period, after which crossover occurred. Pain intensity at rest was the primary outcome measure, while physical and emotional function, global improvement, side effects, and clinical measures were additional outcome measures. There was no main difference between drugs (ANOVA; P=.163), but there was a significant time effect (P<.001), so BTX-A reduced mean (SD) percent change of pain intensity by 30 (33%) after 1month and by 23 (30%) after 3months compared to 11 (40%) and 4 (33%) for saline. The number of patients who received a 30% pain reduction was not significantly larger for BTX-A than after saline at any follow-up visit. The number needed to treat was 11 after 1month and 7 after 3months. There were no significant changes after treatment in any other outcome measures, with the exception of pain on palpation, which decreased 3months after saline injection (P<.05). These results do not indicate a clinical relevant effect of BTX-A in patients with persistent myofascial TMD pain. Botulinum toxin type A is not an effective adjunct to conventional treatment in persistent myofascial temporomandibular disorders.

Copyright © 2011 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.

PMID:
21514731
[PubMed - as supplied by publisher]

Sunday, April 3, 2011

HEADACHES AND MYOFASCIAL TRIGGER POINTS: HIGH POWER ULTRASOUND VS TRIGGER POINT INJECTIONS EQUIVILANT FOR TRAPEZIUS MUSCLE TPs

I have found that trigger point injections are extremely effective in reducing tension-type headaches and frequently can completely eliminate them when combined with a neuromuscular orthotic. This current study from the Archives of Physical Medicine and Rehabilitation shows high-power ultrasound as effective as trigger point injections in treating the Trapezius muscle.

The Trapezius muscle is a large easily treated muscle that can cause referred headache pain. Trigger point injections took less therapy sessions but there was equal effectiveness to both treatments. When treating headaches many of the muscles that cause tension-type headaches are not good candidates for high-power ultrasound. Treating headaches without medication usually requires elimination of muscle trigger points. Neuromuscular Dentistry uses Ultra-Low Frequency TENS to eliminate the underlying cause of Trigger Points and headaches. Trigger Point injections and and Spray and Stretch as described by Travell and Simons is extremely effective in eliminating and preventing re-occurence of trigger points that cause tension-type headaches.

This new study (see abstract below) shows that high-power ultrasound was as effective as trigger point injections when treating trapezius pain and reduction in motion. Treatment of headaches is usually much more effective with trigger point injections. Ultrasound is of little use in treating medial and lateral pterygoid muscles, TMJ oints, Temporalis Muscles, and supra and ifra hyoid muscles.

Tension-Type headaches and Myofascial trigger points are frequently triggers for Migraines.

The use of a diagnostic neuromuscular orthotic is a safe and effective method to evaluate patient's response to Neuromuscular Dentistry. I sometimes consider utilizing trigger point injections, spray and stretch techniques, SPG blocks and other treatment modalities as cheating. Neuromuscular dentistry is such a powerful tool but utilizing these other procedures can drastically enhance the therapeutic effect.


Arch Phys Med Rehabil. 2011 Apr;92(4):657-62.
Comparison of high-power pain threshold ultrasound therapy with local injection in the treatment of active myofascial trigger points of the upper trapezius muscle.
Unalan H, Majlesi J, Aydin FY, Palamar D.

Department of Physical Medicine and Rehabilitation, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey.
Abstract
Unalan H, Majlesi J, Aydin FY, Palamar D. Comparison of high-power pain threshold ultrasound therapy with local ınjection in the treatment of active myofascial trigger points of the upper trapezius muscle.

OBJECTIVE: To compare the effects of high-power pain threshold ultrasound (HPPTUS) therapy and local anesthetic injection on pain and active cervical lateral bending in patients with active myofascial trigger points (MTrPs) of the upper trapezius muscle.

DESIGN: Randomized single-blinded controlled trial.

SETTING: Physical medicine and rehabilitation department of university hospital.

PARTICIPANTS: Subjects (N=49) who had active MTrPs of the upper trapezius muscle.

INTERVENTIONS: HPPTUS or trigger point injection (TrP).

MAIN OUTCOME MEASURES: Visual analog scale, range of motion (ROM) of the cervical spine, and total length of treatments.

RESULTS: All patients in both groups improved significantly in terms of pain and ROM, but there was no statistically significant difference between groups. Mean numbers of therapy sessions were 1 and 1.5 in the local injection and HPPTUS groups, respectively.

CONCLUSIONS: We failed to show differences between the HPPTUS technique and TrP injection in the treatment of active MTrPs of the upper trapezius muscle. The HPPTUS technique can be used as an effective alternative to TrP injection in the treatment of myofascial pain syndrome.

Copyright © 2011 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.
PMID: 21440713 [PubMed - in process]

Tuesday, February 1, 2011

Why you want to find the most experienced Neuromuscular Dentist to Treat TMJ, TMD, Headaches and Migraines.

Neuromuscular Dentistry can give incredible relief of headaches, TMJ symptoms migraines and numerous other chronic pain disorders. It is important to chose your Neuromuscular Dentist wisely.

The International College of CranioMandibular Disorders is dedicated to the field of Neuromuscular Dentistry. It was founded by Dr Barney Jankelson the father of Neuromuscular Dentistry and all the great teachers and researchers in the field have supported ICCMO. The ICCMO website is http://www.iccmo.org/

I strongly suggest that you search for an experienced neuromuscular dentist but also a dentist who is well versed in other areas of pain management and treatment. I am a Diplomate of the American Academy of Pain Management, and a member of American Academy of Craniofacial pain, The American Equilibration Society and well as a Fellow of ICCMO. I utilize Neuromuscular Dentistry whenever I treat chronic pain but I have learned many valuable techniques from my colleagues in these other groups as well. I know that when I attend the AES meeting later this month many of the top neuromuscular dentists will be in attendance. The AES is primarily comprised of Centric Relation dentists but they tops in their field as well.
While I firmly believe the Neuromuscular approach is ideal many of these practioners have excellent results as well. It is incredibly important that your dentist is always in search of continuing knowledge. Excellence demands that practitioners are constantly learning as well as evaluating and reevaluating their techniques and beliefs.

The treatment of Myofascial pain, trigger point injections, spray and stretch, spenopalatine ganglion blocks, prolotherapy are just a few of the effective treatments that are used in conjuction with Neuromuscular Dentistry to improve patients lives. Over the last 35 years of continuing education after graduating dental school I have learned many of these procedures from excellent practitioners who are not neuromuscular dentists. Many of my teachers were physicians, osteopaths, massage therapists, accupuncturists, psychologists, ENT's, Chiropracters and othe diverse mainstream and alternative practitioners.

The American Equilibration Society asked me to contribute an article on Neuromuscular Dentistry for publication. They have graciously allowed it to be reprinted in the ICCMO anthology and in Sleep and Health Journal where it is available at no charge @ http://www.sleepandhealth.com/neuromuscular-dentistry

Neuromuscular Dentistry is a valuable tool that helps clinicians in diagnosing and treating craniomandibular disorders. It is not the only tool. The expression that if you only have a hammer everyone looks like a nail describes what happens when a neuromuscular dentist does not remove his/her blinders and see the big picture. The hammer is an extremely effective tool, but only one of many.

Do not let your life slip by marred by chronic pain that may be alleviated or eliminated by judicious application of neuromuscular dentistry.

In the same way Neuromuscular Dentistry is an important tool (maybe even the most important tool) but it is certainly not the only tool. Experienced neuromuscular dentists utilize a wide variety of approaches in treating their patients to a neuromuscular position to obtain the best possible results.

Monday, January 24, 2011

CONTINUOS HEADACHE FOR MONTHS!

DEBBIE: i have had a headache non stop for 21 months. i need help now!!!!!!
The doctdors can not tell me what is causing thsi, they just keep giving me drugs.

DR SHAPIRA RESPONSE: Debbie, I frequently hear stories like yours. The fact that the physicians cannot find a cause is good news. It means there isn't a brain tumor or similar organic disorder. The majority of headaches are neuromuscular in orgin and you are probably an excellent canidate for diagnostic blocks, trigger pint deactivation and a neuuromuscular orthotic that addresses the trigeminal nerve and the muscles it feeds.

You did not discuss what tests you have had or your history prior to the headache. I advise that you continual to lookfor the underlying causes of your pain.

Long term like you are experiencing can creat permanent brain changes thru central sensitization.

Friday, September 24, 2010

Trigger point injections are an essential part of TMD, Migraine and Headache treatment for many patients

The importance of this study though extremely limited is that it explains why understanding Myofascial Pain and Dysfunction is essential when chronic pain problems including neck pain, headache and TMD disorders. In this study a single injection in the trapezius muscle (shoulder) gave significant reduction in pain in the masseter region along with reduction in EMG values.

There are hundreds of trigger point areas. It is essential to see a physiian or dentist who understands Myofascial Pain and knows how to preform trigger point injections as well as trigger point deactivation with vapocoolants.

Treating patients with drugs and not addressing underlying causes of pain is like painting your ceiling every time it rains instead of fixing where your roof leaks. Neuromuscular Dentistry is used to create a healthy environment where trigger points do not return.

Pain. 1993 Dec;55(3):397-400.
Reduction of pain and EMG activity in the masseter region by trapezius trigger point injection.
Carlson CR, Okeson JP, Falace DA, Nitz AJ, Lindroth JE.

Department of Psychology, College of Dentistry, University of Kentucky, Lexington 40536.
Abstract
In this open, uncontrolled trial, 20 patients with upper trapezius muscle trigger point pain and ipsilateral masseter muscle pain received a single trigger point injection of 2% lidocaine solution (without epinephrine) in the upper trapezius muscle. Following the trapezius injection, there was a significant (P < 0.001) reduction in pain intensity ratings for pain in the masseter region. In addition, there was a significant (P < 0.03) reduction in EMG activity in the masseter muscle. Overall, however, a significant relationship between EMG activity in the masseter and the self-report of pain was not found with the present data set. These clinical findings support the contention that sources of deep pain can produce heterotopic sensory and motor changes in distant anatomical regions.

PMID: 8121703 [PubMed - indexed for MEDLINE]

Tuesday, July 20, 2010

NERVE BLOCKS AND TRIGGER POINT INJECTIONS IN THE TREATMENT OF CHRONIC HEADACHES

A new study "Patterns of use of peripheral nerve blocks and trigger point injections among headache practitioners in the USA: Results of the American Headache Society Interventional Procedure Survey (AHS-IPS)" in Headache found widespread use of trigger point injections and nerve blocks it headache treatment. Many Neuromuscular dentists have a great deal of expertise in the utilization of these injections as part of coordinated treatment for Migraines, Tension-Type headaches and TMJ disorders.

Neuromuscular Dentists recognize that these injections are effective but do not address the underlying causes of patients problems. Correction of the Neuromuscular relationships and trigeminal nerve innervated muscles function is the key to long term correction of these problems. When diagnostic blocks and trigger points are effective the next step is to utilize a diagnostic orthotic to reduce noxious input to the Trigeminal nervous system and correct underlying postural pathology.

Headache. 2010 Jun;50(6):937-42.
Patterns of use of peripheral nerve blocks and trigger point injections among headache practitioners in the USA: Results of the American Headache Society Interventional Procedure Survey (AHS-IPS).
Blumenfeld A, Ashkenazi A, Grosberg B, Napchan U, Narouze S, Nett B, DePalma T, Rosenthal B, Tepper S, Lipton RB.

The Headache Center of Southern California, Encinitas, CA, USA.
Comment in:

Headache. 2010 Jun;50(6):953-4.
Abstract
BACKGROUND: Many clinicians use peripheral nerve blocks (NBs) and trigger point injections (TPIs) for the treatment of headaches. Little is known, however, about the patterns of use of these procedures among practitioners in the USA. OBJECTIVES: The aim of this study was to obtain information on patterns of office-based use of peripheral NBs and TPIs by headache practitioners in the USA. METHODS: Using an Internet-based questionnaire, the Interventional Procedures Special Interest Section of the American Headache Society (AHS) conducted a survey among practitioners who were members of AHS on patterns of use of NBs and TPIs for headache treatment. RESULTS: Electronic invitations were sent to 1230 AHS members and 161 provided usable data (13.1%). Of the responders, 69% performed NBs and 75% performed TPIs. The most common indications for the use of NBs were occipital neuralgia and chronic migraine (CM), and the most common indications for the use of TPIs were chronic tension-type headache and CM. The most common symptom prompting the clinician to perform these procedures was local tenderness at the intended injection site. The most common local anesthetics used for these procedures were lidocaine and bupivacaine. Dosing regimens, volumes of injection, and injection schedules varied greatly. There was also a wide variation in the use of corticosteroids when performing the injections. Both NBs and TPIs were generally well tolerated. CONCLUSIONS: Nerve blocks and TPIs are commonly used by headache practitioners in the USA for the treatment of various headache disorders, although the patterns of their use vary greatly.

PMID: 20618812 [PubMed - in process]

Wednesday, March 17, 2010

MYOFASCIAL EXAMINATION LEADS TO DIAGNOSIS AND SUCCESSFUL TREATMENT OF MIGRAINE HEADACHE

A new article in the Journal of Musculoskeletal Pain by Michael Sorrell, MD of Tufts University showed excellent results in treating Migraine utilizing trigger point injections and physical therapy with supervised home stretching. The examination of the myofascial trigger points is a step rarely done in working up migraine patients,The majority of patients had received previous diagnosis of migraine and had undergone unsuccessful drug treatment. These patients were unaware that their pain could be referred from muscles until the examination of the muscles revealed the referred pain.

The examination did not include all of the the masticatory muscles but did include masseter and temporalis muscles,the sternocleidomastoid muscle,the trapezius muscle, the corrugater supercilius, the semispinalis, splenius cevicus and capitus muscles, as well as the suboccipitalis and levator scapulae muscles. If muscle palpation examination reproduced the headache the patients were included in the trial.

This study only included patients with chronic migraine and migraine without aura whose pain could be reproduced from muscle examination. A subgroup of 11 patients with Migraine with aura (5 of 11 patients migraine symptoms reproduced on examination) was also included in the study. Those patients did remarkably well with 68% mean improvement in those receiving physical therapy and home stretching compared to 5% improvement in the group not utilizing physical medicine. Over 88% of the study group reported over 50% improvment.

This is an important article primarily because it is from a neurology group treating migraines. It is well known that tension type headaches respond to physical medicine and treatment of myofascial trigger point. Migraines are usually very responsive to physical medicine as well. The field of Neuromuscular Dentistry actively focuses on the elimination trigger through use of TENS, TP injections, Spray and Stretch and other techniques as well. More importantly use of neuromuscular trigger points prevents the formation of new trigger points.

The examination in the above article ignored many of the masticatory muscles known to creat migraine like symptoms.

There is also an important concept of myofascial triggers serving as a trigger for migraines. Removal of these triggers can eliminate future migraines.

I have frequently seen migraine patients achieve complete relief thru a combination of a neuromuscular diagnostic orthotic and physical medicine modalities. I have seen other patient who have greatly reduced frequency of migraine but when a migraine does occur medication is still necessary due to severity. This is common with hormonal headaches and migraines. I will have a patient with severe diaily migraines that are eliminated but the patient qwill still have a tension type headache or migraine at ovulation or prior to Menses.

These are patients who I believe we have relieved the myofascial components of their pain but the hormonal triggers remain. The headaches that are then present are less severe. Other patients may only get the aura when presented with triggers but no pain. I do believe that evaluation and elimination of myofascial triggers is important for all migraine patients but in some patients the myofacial trigger points are a secondary result of the migraine pain rather that a primary cause of migraine. It is still important to eliminate these secondary trigger points so the do not increase and become a primary problem.

Saturday, February 6, 2010

Trigger point injections and Greater Occipital Nerve block treating transofrmed migraine. The Role of Neuromuscular Dentistry in Long Term Relief

Transformed Migraine (common Migraine) usually has a history of beginning as episodic migraine attacks which increse in frequency. This occurs over aperiod of months to years and the Transformed Migraine (TM) occur frequently, often daily and are a combination of vascular and Tension-type Headaches. The TM can very from mild to moderate severity with epsodes of increased severity. These headaches usually begin in teen years or early 20's. Transformed Migraine attacks are frequently accompanied by nauseau, phonophobia (sensitivity to noise), photophobia (sensitivity to light) which lessen over time. A large porportion of patients are women with 90% of whom have a history of migraine without aura.

Patients with Transformed Migraines frequently report a vascular quality, that exhibits a throbbing nature. In some cases, it can be difficult to distinguish between tension-type headaches and TM. These headaches are also identical to headaches frequently seen in patients with TMD or temporomandibular dysfunction. The history of headaches beginning in teen years and usually women fit the profile of TMD sufferers. There is a theory that all headaches are a combination of neurovascular and muscular headache pain. In this view of headaches the muscular or tension-type headache can trigger the vascular (or neurogenic) headache and the Vascular (or neurogenic ) headache can serve trigger the muscular headache. This theory always fits headaches arising from the trigeminal nervous system because it controls meningeal blood flow and masticatory muscles.

These headaches usually respon beautifully to treatment with a neuromuscular orthotic which can frequently eliminate the majority of pain. Some patients, especially those with long standing pain have developed myofascial trigger points that are not completely relieved by TENS and an orthotic. Those patients frequently can be helped by manual trigger point therapy, trigger point injections and/or nerve blocks to break up myofascial trigger points.

Unfortunately clinical studies have shown that almost 80% of these patients overuse symptomatic medications. This medication over-use can frequently increase migraine occurrence. The development of Medication Overuse Headache (MOH), also known as Rebound Headache is often seen with daily use of analgesics, either prescription or over-the-counter. Other risk factors for TM or CM include high life stress (as seen in TMJ or TMD patients), snoring and /or sleep apnea a TMJ disorder according to the NHLBI (http://www.nhlbi.nih.gov/meetings/workshops/tmj_wksp.pdf), head injury and history of orofacial trauma including wisdom teeth extraction and/or orthodontics (especially involving 4 bicuspid extraction).

Depression and anxiety are features shared by patients with Migraine, TMJ disorders, Tension-type headaches and Chronic Daily Headaches. Healthy lifestyle habits including sleeping, eating and exercising are important for all of these disorders. The typical neurologist will prescribe a variety of preventive therapies including Antidepressant and Anticonvulsant medications for transformed Migraine with a goal of reverting the headaches back from daily to episodic attacks. The Neuromuscular Dentist approach is to eliminate the myofascial pain by use of TENS and a neuromuscular orthotic and eventually eliminate the nociceptive input to the brain to eliminate the original migraineor vascular headache. The original migraine is usually a result of unhealthy neuromuscular input from the trigeminal nerve or airway collapse at night due to uderlying jaw pathology that leads to snoring, sleep apnea and upper airway resistance syndrome (sleep distrubance known to cause/promote fibromyalgia)

The use of triggr point infections is a way to hasten recovery when utilizing neuromuscular dentistry. An article in The Journal of Neurology, Neurosurgery and Psychiatry examined the effect of greater occipital nerve blocks and trigger point injections on Transformed Migraine (pubmed abstract below). The article compared these proceedures with and without use of triamcinolone which the authors concluded was unnecessary for the therapeutic effect. The therapeutic effect was impressive, there was immediate reduction in pain (3.2 points) and neck pain was reduced(1.5 points) and resulted in 2.7/3.8 headache free days. Th results were equal with or without the steroid. The use of anaesthetic injections to turn off migraine pain is effective for a short period of time but when combined with neuromuscular dentistry and the use of TENS and an orthotic to prevent recurrence of the problem can be part of a long term correction of this difficult problem.

Another article in Cranio (pubmed abstract below) "Botulinum toxin, lidocaine, and dry-needling injections in patients with myofascial pain and headaches." compared treatment of myofascial trigger points with three different methods.They found that " Statistically, all the groups showed favorable results for the evaluated requisites" "Considering its reduced cost, lidocaine could be adopted as a substance of choice, and botulinum toxin should be reserved for refractory cases, in which the expected effects could not be achieved, and the use of a more expensive therapy would be mandatory." The treatment of myofascial trigger points successly treated the headaches. Breaking up the trigger points with the injection or the needle is effecteive without botulinum toxin or steroid use. Use of manual medicine, myotherapy and /or massage will also brek-up trigger points. Regardless of the method of eliminating the trigger points long term relief will depend on eliminating the noxious input to the trigeminal nervous system for long term relief. The use of the diagnostic neuromuscular dentistry orthotic is essential for most patients wanting to avoid a lifetime of drug use to treat the condition.

Yet another study in Headache (pubmed abstract below) "Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study." found very significant relief of headache pain of ETTH, Episodic Tension-Type Headaches by treatment of Cervical Myofacial Trigger Points. The study showed that trigger point injection with saline gave good results for up to 12 weeks where the Botox results did last for longer periods. Again this is a case calling for combination therapy of a Neuromuscular dentistry diagnostic orthotic and trigger point injections. Utilizing the combination should cause long term elimination of myofascial trigger points. Many patients will nor require the trigger point injections but they are helpful for difficult cases and to decrease treatment time with the diagnostic orthotic.

A diagnostic orthotic is used in Neuromuscular Dentistry (http://www.sleepandhealth.com/neuromuscular-dentistry) to eliminate pain and symptoms prior tolong term correction. This 2 phase treatment protocol allows patient neuromuscular stabilization and pain relief before making any irreverible occlusal changes.

One additional PubMed article is included below "The effects of greater occipital nerve block and trigger point injection on brush allodynia and pain in migraine." which evaluated the effect of Greater Occipital Nerve Block on Migraine and
allodynia. Allodynia is when a stimulus that is not normally perceived as painful causes pain. The study had 19 patients and 17 or almost 90% had headache relief. All 19 patients had relief of allodynia. Neuromuscular Dentists should learn to use trigger point injections and Greater Occipital Nerve Blocks as part of comprehensive phase 1 treatment with neuromuscular orthotics to increase pain relief. Long term relief without the chronic use of drugs is ideally and frequently attainable with Neuromuscular Dentistry.

The Las Vegas Institute now teaches stimulation of the Accesory Nerve (cranial nerve XI) along with the Trigeminal Nerve (cranial nerve V) when utilizing TENS to relax muscles i


J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):415-7. Epub 2007 Aug 6.
Greater occipital nerve block using local anaesthetics alone or with triamcinolone for transformed migraine: a randomised comparative study.
Ashkenazi A, Matro R, Shaw JW, Abbas MA, Silberstein SD.

Department of Neurology, Thomas Jefferson University, 111 South 11th Street, Suite 8130, Philadelphia, PA 19107, USA. avi.ashkenazi@jefferson.edu
OBJECTIVE: To determine whether adding triamcinolone to local anaesthetics increased the efficacy of greater occipital nerve block (GONB) and trigger-point injections (TPIs) for transformed migraine (TM). METHODS: Patients with TM were randomised to receive GONB and TPIs using lidocaine 2% and bupivacaine 0.5% + either saline or triamcinolone 40 mg. We assessed the severity of headache and associated symptoms before and 20 minutes after injection. Patients documented headache and severity of associated symptoms for 4 weeks after injections. Changes in symptom severity were compared between the two groups. RESULTS: Thirty-seven patients were included. Twenty minutes after injection, mean headache severity decreased by 3.2 points in group A (p<0.01) and by 3.1 points in group B (p<0.01). Mean neck pain severity decreased by 1.5 points in group A (p<0.01) and by 1.7 points in group B (p<0.01). Mean duration of being headache-free was 2.7+/-3.8 days in group A and 1.0+/-1.1 days in group B (p = 0.67). None of the outcome measures differed significantly between the two groups. Both treatments were well tolerated. CONCLUSIONS: Adding triamcinolone to local anaesthetics when performing GONB and TPIs was not associated with improved outcome in this sample of patients with TM.

PMID: 17682008 [PubMed - indexed for MEDLINE]

Cranio. 2009 Jan;27(1):46-53.
Botulinum toxin, lidocaine, and dry-needling injections in patients with myofascial pain and headaches.
Venancio Rde A, Alencar FG Jr, Zamperini C.

Marquette University School of Dentistry TMD and Orofacial Pain, P.O. Box 1881 Milwaukee, WI 53201-1881, USA.
Trigger point injections with different solutions have been studied mainly with regard to the management of myofascial pain (MFP) patient management. However, few studies have analyzed their effect in a chronic headache population with associated MFP. The purpose of this study was to assess if trigger point injections using botulinum toxin, lidocaine, and dry-needling injections for the management of local pain and associated headache management. Forty-five (45) myofascial pain patients with headaches that could be reproduced by activating at least one trigger point, were randomly assigned into one of the three groups: G1, dry-needling, G2, 0.25% lidocaine, at 0.25% and G3 botulinum toxin and were assessed during a 12 week period. Levels of pain intensity, frequency and duration, local postinjection sensitivity, obtainment time and duration of relief, and the use of rescue medication were evaluated. Statistically, all the groups showed favorable results for the evaluated requisites (p < or = 0.05), except for the use of rescue medication and local post injection sensitivity (G3 showed better results). Considering its reduced cost, lidocaine could be adopted as a substance of choice, and botulinum toxin should be reserved for refractory cases, in which the expected effects could not be achieved, and the use of a more expensive therapy would be mandatory.

PMID: 19241799 [PubMed - indexed for MEDLINE]

Headache. 2009 May;49(5):732-43. Epub 2008 Oct 24.
Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study.
Harden RN, Cottrill J, Gagnon CM, Smitherman TA, Weinland SR, Tann B, Joseph P, Lee TS, Houle TT.

Center for Pain Studies, Rehabilitation Institute of Chicago, 446 E. Ontario, Chicago, IL 60611, USA.
OBJECTIVE: To evaluate the efficacy of botulinum toxin A (BT-A) as a prophylactic treatment for chronic tension-type headache (CTTH) with myofascial trigger points (MTPs) producing referred head pain. BACKGROUND: Although BT-A has received mixed support for the treatment of TTH, deliberate injection directly into the cervical MTPs very often found in this population has not been formally evaluated. METHODS: Patients with CTTH and specific MTPs producing referred head pain were assigned randomly to receive intramuscular injections of BT-A or isotonic saline (placebo) in a double-blind design. Daily headache diaries, pill counts, trigger point pressure algometry, range of motion assessment, and responses to standardized pain and psychological questionnaires were used as outcome measures; patients returned for follow-up assessment at 2 weeks, 1 month, 2 months, and 3 months post injection. After 3 months, all patients were offered participation in an open-label extension of the study. Effect sizes were calculated to index treatment effects among the intent-to-treat population; individual time series models were computed for average pain intensity. RESULTS: The 23 participants reported experiencing headache on a near-daily basis (average of 27 days/month). Compared with placebo, patients in the BT-A group reported greater reductions in headache frequency during the first part of the study (P = .013), but these effects dissipated by week 12. Reductions in headache intensity over time did not differ significantly between groups (P = .80; maximum d = 0.13), although a larger proportion of BT-A patients showed evidence of statistically significant improvements in headache intensity in the time series analyses (62.5% for BT-A vs 30% for placebo). There were no differences between the groups on any of the secondary outcome measures. CONCLUSIONS: The evidence for BT-A in headache is mixed, and even more so in CTTH. However, the putative technique of injecting BT-A directly into the ubiquitous MTPs in CTTH is partially supported in this pilot study. Definitive trials with larger samples are needed to test this hypothesis further.

PMID: 19178577 [PubMed - indexed for MEDLINE]

Headache. 2005 Apr;45(4):350-4.
The effects of greater occipital nerve block and trigger point injection on brush allodynia and pain in migraine.
Ashkenazi A, Young WB.

Department of Neurology, Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.
OBJECTIVE: To evaluate the effect of GONB, with or without trigger point injection (TPI), on dynamic mechanical (brush) allodynia (BA) and on head pain in migraine. Background.-Patients with migraine often have cutaneous allodynia that is related to sensitization of central pain neurons. Greater occipital nerve block (GONB) is an effective treatment for migraine headache; however, its effect on cutaneous allodynia in migraine is unknown. METHODS: We studied patients with migraine and BA who were treated with GONB with or without TPI. Demographic data, migraine history, and headache features were documented. Allodynia was evaluated using a structured questionnaire and by applying a 4 x 4-inch gauze pad to skin areas in the trigeminal and cervical dermatomes. Degree of allodynia (the allodynia score) was measured on a 100-mm visual analog scale (VAS) before treatment and 10 and 20 minutes thereafter. Headache levels were assessed using an 11-point verbal scale. Allodynia scores, as well as headache levels, before and after treatment were compared. RESULTS: Nineteen patients were studied. Mean age was 43.6+/-11.8 years. Twenty minutes after treatment, headache was reduced in 17 patients (89.5%) and did not change in 2 (10.5%). The average headache level was 6.53 before treatment and 3.47, 20 minutes after it. The average allodynia score decreased after 20 minutes in all patients. Average allodynia score per site was reduced by 18.69 mm and 13.74 mm in the trigeminal and cervical areas, respectively. There was a positive correlation between allodynia index, obtained through the questionnaire, and allodynia score, obtained by examination. CONCLUSION: GONB, with or without TPI, reduced both head pain and brush allodynia in this migraine patient group.

PMID: 15836572 [PubMed - indexed for MEDLINE]